CA002-001
54 evidence topics · 5 sources
Objective
Primary and secondary objectives
“The primary objective was to establish the safety, tolerability and Maximum Tolerated Dose (MTD) of BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The secondary objectives were to assess pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry statement of purpose
Location and study date
Registry status, dates, and sites
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “CA002-001” |
| Sponsor | “Bristol-Myers Squibb” |
| Overall status | “Terminated” |
| Reason stopped | “(Non-safety reason, business objectives have changed)” |
| Study start | “2013-11” |
| Primary completion | “2016-03” |
| Study completion | “2016-03” |
| United States site | “Usc/Norris Comprehensive Cancer Center” |
| Site cities | “Los Angeles”; “Parkville”; “Vancouver”; “Toronto” |
Study design
Open-label, multi-arm phase 1 dose escalation
“In this open label phase I dose escalation study, BMS-986115 was administered as an oral single agent on once daily continuous (QD) and two times weekly intermittent (BIW) schedules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was an ascending multiple-dose Phase I study and conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Arm A and Arm B were conducted in a sequential manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accelerated titration followed by a 3 + 3 design
“The dose escalation phase was initially conducted using an accelerated titration design [18] in which a single subject was enrolled in each cohort, and was switched to a 3 + 3 design with modified Fibonacci dose escalation if any of the following occurred in a single-subject cohort: grade 2 treatment-related diarrhoea lasting >36 h despite appropriate medical management; or any other grade 2 treatment-related adverse advent (AE), excluding asymptomatic electrolyte abnormalities that were manageable with appropriate supplements, alopecia and fatigue lasting ≤5 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For single-subject cohorts, dose escalation occurred in increments of 100% above the previous dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose escalation continued until the MTD was established or until the sponsor and investigators concurred that further dose escalation was not warranted. Once MTD was established in a given study arm, approximately 6 additional subjects were to be treated in a dose expansion cohort, at a dose equal to or below the MTD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Non-Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Treatment” |
| Arms | “Arm A: Dose Escalation (BMS-986115)”; “Arm A: Dose Expansion (BMS-986115)”; “Arm B: Dose Escalation (BMS-986115)”; “Arm B: Dose Expansion (BMS-986115)” |
Sponsor and population as described by Immunome
Eligibility criteria
Advanced solid tumours refractory to or relapsed from standard therapies
“Male and female subjects who were 18 years or older and had a histological or cytological diagnosis of advanced solid tumours refractory to or relapsed from standard therapies were eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The inclusion criteria included life expectancy of ≥3 months, ECOG performance status 0–1, and adequate organ function including ECG parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects were required to have an adequate lipid profile as increases in triglycerides were seen in the multiple dose rat study with BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Main exclusion criteria
“The main exclusion criteria were: symptomatic or unstable brain metastases, any serious medical disorders including active infection and significant cardiovascular disease, major thromboembolic events or bleeding diathesis within 6 months of study entry, current or recent GI disease that increases the risk of diarrhoea, any major surgery or GI disorder that would interfere with administration of oral medications, conditions requiring chronic systemic glucocorticoid use, therapeutic anticoagulation, and concomitant second malignancies (except adequately treated in situ cancers and non-melanomatous skin cancers).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior exposure to BMS-986115 or other Notch inhibitors was not allowed and those with a history of allergy to Notch inhibitors including BMS-986115related compounds were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Washout and prohibited concomitant medications
“Patients required a washout period of at least 6 months for prior therapy with nucleoside analogues, 6 weeks for prior therapy with nitrosoureas, mitomycin C and liposomal doxorubicin and 4 weeks for other anticancer therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry criteria for gastrointestinal disease and hypertriglyceridemia
Treatment
Dose levels in the once-daily and twice-weekly arms
Cycle structure and dosing days
“In the treatment period, the first cycle was 7 days in duration, and all subsequent cycles were 28 days in duration. Subjects received a single dose of BMS-986115 on Cycle 1 Day 1. In Cycle 2 and all subsequent cycles, subjects in Arm A received QD doses of BMS-986115 (i.e., Day 1 to Day 28 inclusive) and subjects in Arm B received BIW doses of BMS-986115 (i.e., Days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose interruption, dose reduction, and treatment duration
“Dose interruption (up to 28 days) and/or dose modification (up to 2 dose reductions) were permitted in the event of study drug toxicity. Subjects could continue to receive treatment in the study until they experienced disease progression, unacceptable AEs, or withdrew consent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Gastrointestinal toxicity as the dose-limiting effect of Notch inhibition
“In animal studies, the main pharmacological toxicities included dose-dependent gastrointestinal (GI) toxicity, lymphoid depletion, and interruption of ovarian follicle maturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As prolonged inhibition of the Notch pathway is associated with increased GI toxicity, an oral Notch inhibitor with a short half-life that allows transient rather than continuous target engagement is desirable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical development of Notch inhibitors has been hampered by on-target GI toxicity and most drugs have not been tolerable at daily continuous schedule [19–21].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-limiting toxicity period and definition
“DLT period was 35 days (from C1, duration of which was 7 days, to end of cycle 2, duration of which was 28 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gr ≥3 diarrhoea lasting >24 h despite appropriate medical management; any other drug-related Gr ≥3 non-hematologic AE, except hyperlipidemia in subjects not receiving maximum medical management or electrolyte abnormalities that may be managed with supplements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcome: safety and tolerability
Safety assessments
“Safety assessments consisted of physical examination, vital signs, weight, performance status assessment using ECOG (Eastern Cooperative Oncology Group) criteria and documentation of AEs and serious AEs (SAEs) for all treated subjects using the National Cancer Institute’s Common Toxicity Criteria for Adverse Events v4.03.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: pharmacokinetics of BMS-986115 and BMT-100948
“Pre and post treatment EDTA peripheral whole blood samples for the PK determination of BMS-986115 and its equally active metabolite BMT-100948 were collected on days 1 (pre-dose and 0.5, 1, 1.5, 2, 4, and 8 h post-dose), 2 (24 h post first dose), 3 (48 h post first dose), 4 (72 h post first dose) and 5 (120 h post first dose) of cycle 1 for both Arm A and Arm B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma concentrations of BMS-986115 and BMT-100948 were determined using a validated liquid chromatography-tandem mass spectrometry assay.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: Notch pathway gene expression as a pharmacodynamic biomarker
“Expression of Notch pathway-related genes in peripheral blood was measured as surrogate PD biomarkers for BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The level of inhibition of Hes1 and Deltex1 expression by oral doses of BMS-986115 in peripheral blood was measured as surrogate PD biomarkers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: preliminary anti-tumour activity by RECIST 1.1
“Tumour assessments by CT or MRI were performed at baseline and approximately every 8 weeks during treatment, and at the end of treatment or 30-day follow-up if not done within the preceding 8 weeks. The radiological response to therapy was assessed using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry secondary outcome: investigator-assessed tumor response
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm
Participants treated and evaluable for dose-limiting toxicity
“A total of 36 patients were treated in the study (24 in Arm A and 12 in Arm B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 24 patients treated in Arm A, 20 patients were DLT evaluable for 5 QD dose levels evaluated (0.3 mg [N = 2], 0.6 mg [N = 2], 1.2 mg [N = 5], 1.5 mg [N = 6], and 2 mg [N = 5]) (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 12 patients treated within Arm B, 10 were DLT evaluable for 3 BIW dose levels (2 mg [N = 2], 4 mg [N = 2], and 8 mg [N = 6]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants treated per dose level
| Dose level | Total no. of patients | No. of DLT evaluable patients |
|---|---|---|
| Arm A, 0.3 mg once daily | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm A, 0.6 mg once daily | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm A, 1.2 mg once daily | “6”View highlighted excerpt for this quote | “5”View highlighted excerpt for this quote |
| Arm A, 1.5 mg once daily | “7”View highlighted excerpt for this quote | “6”View highlighted excerpt for this quote |
| Arm A, 2.0 mg once daily | “7”View highlighted excerpt for this quote | “5”View highlighted excerpt for this quote |
| Arm B, 2 mg twice weekly | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm B, 4 mg twice weekly | “2”View highlighted excerpt for this quote | “2”View highlighted excerpt for this quote |
| Arm B, 8 mg twice weekly | “8”View highlighted excerpt for this quote | “6”View highlighted excerpt for this quote |
Description of analysis sets
Safety and pharmacokinetic populations
“All subjects who received at least one dose of BMS-986115 were evaluated for safety parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma concentration-time data for BMS-986115 and an equally active metabolite BMT-100948 were reported for subjects who received at least one dose of study medication. Non-compartmental analysis (NCA) was performed to characterize the PK parameters for the parent compound (BMS-986115) using nominal time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive statistical analysis
“Demographics, baseline characteristics, safety and efficacy measurements were described using descriptive statistics. For PD analysis, geometric mean relative gene expression data for the Notch pathway genes Deltex1 and Hes1 were plotted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion of CA002-001 participants in a pooled exposure-response safety analysis
Results
Participant disposition
Treatment until progression and discontinuation for adverse events
“Sixteen (67%) of the 24 subjects treated in Arm A and 6 (50%) of the 12 subjects treated in Arm B continued to receive treatment until disease progression. A total of 9 subjects discontinued treatment after experiencing one or more AEs that were either related to study drug (N = 5, 3 subjects in Arm A and 2 in Arm B) or not related to the study drug (N = 4, 2 subjects in each arm).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of treatment
“The median duration of time on treatment was 5.6 weeks (range 0.9–57.9 weeks) for the overall study population, and was similar for subjects in Arm A (median 5.8 weeks, range 1.7–57.9 weeks) and those in Arm B (median 5.5 weeks, range 0.9–48.4 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics, performance status, cancer types, and prior therapy (N = 36)
One participant with desmoid fibromatosis
Efficacy results
Best tumour response and stable disease for more than 6 months
“Of the 36 treated subjects, 21 (58%) subjects had progressive disease and 11 (31%) had stable disease (SD) as a best tumour response and 4 were not evaluable. Of the 11 subjects with SD, 5 (1 clear cell renal cell carcinoma, 1 fibromatosis, 2 adenoid cystic carcinoma, and 1 retroperitoneal liposarcoma) had SD for more than 6 months (Supplementary Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participant with fibromatosis treated at 1.5 mg once daily
“In addition, the patient with fibromatosis, who did not have documented disease progression before study entry, achieved SD with maximum disease shrinkage of 16.5% after ~9 months of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All 3 patients who had prolonged SD with disease shrinkage were treated with the pharmacodynamically active doses of BMS-986115 (1.2 mg QD [renal cell carcinoma case], 1.5 mg QD [fibromatosis case], and 2 mg QD [retroperitoneal liposarcoma case]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participant with desmoid fibromatosis as described by Immunome
Pharmacokinetics: absorption, half-life, and accumulation
“BMS-986115 was rapidly absorbed following single/multiple-dose administration over the 0.3-mg to 8-mg dose range, and the median Tmax was within a range of 1 h to 3 h. There was a dose-related increase for both Cmax and AUCtau after BMS-986115 administration following single/multiple-dose administration over the 0.3-mg to 8-mg dose range. Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median accumulation ratios (AUCtau ratio of Day 15/Day 1 values) of BMS-986115 after once daily dosing were 2.64, 3.9, 3.66, 2.33, and 2.19 for 0.3-, 0.6-, 1.2-, 1.5-, and 2-mg doses, respectively. Accumulation ratios (AUCtau ratio of Day 16/Day 1) of BMS-986115 after two consecutive days dosing in a week (Arm B) were 2.47, 3.01, and 2.77 for 2-, 4- and 8-mg doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics: active metabolite BMT-100948
“Plasma concentrations of BMT-100948 were low relative to plasma concentrations of the parent drug (BMS-986115). Median Cmax% ratios for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 5 to 13%, and after multiple doses on Day 15 ranged from 12 to 16%, respectively. Similarly, median AUCtau ratio for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 14% - 22%, and after multiple doses on Day 15 ranged from 17% - 27%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics: inhibition of Hes1 and Deltex1 expression
“After 2 weeks of dosing at the highest tolerated doses of 1.2 mg QD and 1.5 mg QD, geometric mean relative expression of Hes1 was continuously inhibited by >50% below baseline, with peak inhibition of >80% (Fig. 2). Similarly, geometric mean relative expression of Deltex1 was continuously inhibited by greater than 45% for the entire dosing interval, with peak inhibition of >60% (Fig. 2). At the highest tolerated dose level of 4 mg BIW, geometric mean relative expression of Hes1 was inhibited by >75% for at least 48 h of the weekly dosing cycle and Deltex1 was inhibited by greater than 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Maximum tolerated dose and dose-limiting toxicities in the once-daily arm
“Based on the incidence of DLT, the MTD for QD dosing of BMS-986115 was 1.5 mg QD. At this dose level, 1 DLT (Gr 3 nausea) was observed in one of 6 patients treated. No DLT was observed in 5 evaluable patients treated at 1.2 mg QD. The 2 mg QD dose was not tolerated with DLTs in 3 of the 5 DLT-evaluable patients (Gr 3 ileus; Gr 3 nausea; Gr 3 pruritus/urticaria).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-limiting toxicities in the twice-weekly arm
“None of the two patients treated at 4 mg BIW had DLT. But, a higher dose of 8 mg BIW was not tolerated with DLTs in 2 of the 6 DLT-evaluable subjects (Gr 3 diarrhoea; Gr 3 nausea/dehydration/anorexia with Gr 2 fatigue).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events of any causality and treatment-related adverse events
“There were no treatment-related deaths. Adverse events (AE) were reported in all 36 (100%) subjects. The most frequently reported AEs (>50% of all treated subjects) regardless of causality were diarrhoea (72%), nausea (69%), hypophosphataemia (67%), fatigue (64%), decreased appetite (58%), and vomiting (53%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the QD arm, a dose related trend was apparent in the frequency of GI events but this trend was not observed in the BIW arm (Table 3). The most common treatment-related Gr 3 or 4 AEs were hypophosphataemia (39%), diarrhoea (19%), nausea (11%), hypokalaemia (11%) and hyponatraemia (6%) (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events of all grades by dose level
Serious adverse events
“Overall, SAEs were reported for 18 (50%) subjects. Eight (6 in Arm A and 2 in Arm B) (22%) experienced SAEs that were treatment-related: Gr 3 diarrhoea (Arm B), Grade 3 diarrhoea with Gr 2 abdominal pain (Arm A), Gr 2 diarrhoea with Gr 2 dehydration (Arm A), Gr 3 nausea, dehydration and decreased appetite (Arm B), Gr 3 nausea with Gr 3 fatigue and Gr 4 hypophosphataemia (Arm A), Gr 3 colitis (Arm A), Gr 2 anaemia and Gr 3 pulmonary embolism (Arm A), and Gr 3 ileus (Arm A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation due to adverse events
“Nine subjects (25%) discontinued treatment due to AEs (Table 2), including 5 subjects who discontinued due to treatment-related diarrhoea with or without nausea (N = 3), dermatitis acneiform (N = 1), or dehydration and anorexia (N = 1). Four other subjects discontinued treatment due to non-treatment related AEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 or 4 diarrhoea at the maximum tolerated dose
Study limitations
Summary
- CA002-001 was an open-label, nonrandomized phase 1 dose-escalation study without a comparator arm in 36 participants with advanced solid tumours (24 in the once-daily arm and 12 in the twice-weekly arm). One participant (3%) had desmoid fibromatosis, so the study provides no estimate of efficacy in desmoid tumors; that participant “did not have documented disease progression before study entry” and was treated at 1.5 mg once daily, a dose above the 1.2 mg once-daily dose used in RINGSIDE.
- Six participants received 1.2 mg once daily, and five of them were evaluable for dose-limiting toxicity. The median duration of treatment was 5.6 weeks (range 0.9 to 57.9 weeks), which limits the assessment of adverse events that emerge with longer exposure.
- The study was “terminated early for business reasons”, and the maximum tolerated dose of the twice-weekly schedule was not established. The registry lists the reason as a “Non-safety reason, business objectives have changed” and shows no posted results.
- Tumour response was assessed by the investigator per RECIST 1.1, with no central review reported. All analyses were descriptive.
- The eligibility criteria required ECOG performance status 0 to 1, and the baseline characteristics report one participant (3%) with baseline WHO performance status 2.
- Bristol-Myers Squibb sponsored and funded the study, and six authors were Bristol-Myers Squibb employees and stockholders.
Early termination limits conclusions
“Despite the demonstration of safety and tolerability, our study was terminated early for business reasons making it difficult to ultimately draw any firm conclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is regrettable, however, that we did not manage to perform correlative analyses on tumors to identify potential biomarkers of response in these patients because of early termination of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote